Lynparza’s revenue trends
In 4Q17, AstraZeneca’s (AZN) Lynparza reported revenues of $100.0 million, which reflected ~61.0% growth on a year-over-year (or YoY) basis and ~23.0% growth on a quarter-over-quarter basis.
In fiscal 2017, AstraZeneca’s Lynparza generated revenues of $297.0 million, which reflected ~36.0% growth on a YoY basis.
Lynparza’s regional performance
Lynparza is approved in 57 countries. In 2017, in the US market, Lynparza reported revenues of $141.0 million, which reflected ~11.0% growth on a YoY basis.
In March 2017, the FDA approved Tesaro’s (TSRO) Zejlua for the treatment of Fallopian tube, primary peritoneal and epithelial ovarian cancer. In December 2016, the FDA also approved Clovis Oncology’s (CLVS) Rubraca for treatment of BRCA-mutant ovarian cancer.
Lynparza, Rubraca, and Zejlua are all PARP (poly ADP ribose polymerase) inhibitors. So, during the first half of 2017, AstraZeneca’s Lynparza faced stiff competition from peer drugs Rubraca and Zejlua.
During 2H17, the launch of Lynparza irrespective of BRCA-mutation status in the second-line ovarian cancer setting pushed revenue growth in the United States. In the US market, in 4Q17, Lynparza witnessed 46.0% quarter-over-quarter growth. According to total prescription volumes, Lynparza remained the leading PARP inhibitor in the US market.
In 2017, in the European market, Lynparza generated revenues of $130.0 million, which reflected ~60.0% growth on a YoY basis.
Increasing BRCA-testing rates and successful launch of Lynparza in different European markets primarily attributed to the revenue growth of the drug in Europe. AstraZeneca recently launched Lynparza in Finland and Ireland.
Previously, in July 2017, AstraZeneca and Merck (MRK) entered into a collaboration to jointly develop Lynparza and investigational selumetinib for treatment of different cancers as monotherapy and combination therapies.
In January 2018, the FDA approved AstraZeneca and Merck’s (MRK) Lynparza for use in individuals with deleterious/suspected deleterious germline BRCA-mutated, human epidermal growth factor receptor 2-negative metastatic breast cancer who have previously received chemotherapy.
The FDA approval of Lynparza for label expansion is expected to boost the revenue growth of the drug in 2018.